This study aims to compare the efficacy and safety of a 6-month all-oral regimen including Bedaquiline (BDQ,B), Delamanid (DLM,D), Linezolid (LZD, L), and Levofloxacin (LFX,L) to the the standard long - course treatment regimen within the Chinese population. The main questions it aims to answer are:
Is the efficacy of short regimen non-inferior to standard regimen? Is the short regimen safe enough to replace the standard regimen?
Participants will:
Be given with either short or standard regimen for RR-TB treatment Be asked to complete the scheduled visit as planned.

开始日期2025-09-30

申办/合作机构-

ChiCTR2500108732

/ Not yet recruiting临床2期IIT

A Multicenter, Open-label, Randomized, Active-controlled Clinical Study to Compare the Efficacy and Safety of Different Combination Regimens of JDB0131 Benzenesulfonate Tablets with Delamanid in Patients with Rifampin-resistant Tuberculosis (JD-RISE)

开始日期2025-09-10

申办/合作机构

首都医科大学附属北京胸科医院

[+2]

100 项与德拉马尼相关的临床结果

登录后查看更多信息

100 项与德拉马尼相关的转化医学

登录后查看更多信息

100 项与德拉马尼相关的专利（医药）

登录后查看更多信息

1,262

项与德拉马尼相关的文献（医药）

2025-12-01·TOXICOLOGY AND APPLIED PHARMACOLOGY

Effects of melatonin or physical exercise application in rats with hepatopulmonary syndrome

Article

作者: Brasil, Marilda da Silva ; Assoni, Giorgia ; Engeroff, Millena de Oliveira ; Schemitt, Elizângela Gonçalves ; Marroni, Claudio Augusto ; Marroni, Norma Possa ; Picada, Jaqueline Nascimento ; Fonseca, Sandielly Rebeca Benitez ; Martins, Gabriela Dos Santos ; Dias, Alexandre Simões

Hepatopulmonary syndrome (HPS) is characterized by liver abnormalities, hypoxemia, and intrapulmonary vasodilatation. Currently, liver transplant is the only effective treatment, as there are no established pharmacological therapies for HPS. Bile duct ligation (BDL) is an experimental model widely used to study the pathophysiology of HPS, as it replicates disease abnormalities. This study aimed to evaluate the effects of melatonin (MLT) or physical exercise (EX) on BDL-induced HPS. Twenty-six male Wistar rats were divided into 4 groups: control (CO), BDL, BDL + MLT, and BDL + EX. Starting on day 15, MLT (20 mg/kg) was administered intraperitoneally once daily, and the EX protocol was implemented, consisting of swimming sessions in a 50-cm-deep tank every other day. All animals were euthanized on day 29, when blood, liver, and lung samples were collected for analysis. The BDL group showed significant liver damage, as evidenced by elevated liver enzyme levels, the presence of fibrous septa and nodules in the liver, an increased diameter of intrapulmonary vessels, impaired gas exchange in arterial blood gas analysis, increased oxidative stress, and DNA damage. The BDL + MLT and BDL + EX groups showed liver parenchyma restructuring, reduced intrapulmonary vasodilatation, improved gas exchange, and reduced oxidative stress and DNA damage compared with the BDL group. Our results suggest that both MLT and EX exert beneficial effects on BDL-induced HPS, reducing liver and lung abnormalities, improving antioxidant defenses, and decreasing DNA damage through modulation of the antioxidant system.

2025-12-01·CLINICAL PHARMACOLOGY & THERAPEUTICS

Corrigendum to “Model‐Informed Once‐Daily Dosing Strategy for Bedaquiline and Delamanid in Children, Adolescents and Adults with Tuberculosis”

2025-12-01·Brain and Behavior

MiR‐33‐5p‐opioidergic Signaling Regulates Cognitive Impairment Induced by Bile Duct Ligation in Rats: Ameliorative Role of Naloxone

Article

作者: Arjmand, Ali ; Alani, Behrang ; Mazoochi, Tahere ; Rahimi‐vala, Mohadeseh ; Ardjmand, Abolfazl

ABSTRACT:

Objective:

The present study investigated the involvement of miR‐33‐5p‐opioidergic signaling in the regulation of cognitive impairment induced by bile duct ligation (BDL) in rats, with an emphasis on the ameliorative role of naloxone.

Methods:

Among the four groups of Wistar rats (control, sham, BDL, and BDL + Naloxone [Nalx]), the common bile duct was occluded only in the BDL groups. Fourteen days after BDL induction and following completion of the analysis of the liver function tests of alkaline phosphatase, alanine aminotransferase, aspartate transaminase, direct bilirubin, total bilirubin, gamma‐glutamyl transpeptidase (GGT), and lactate dehydrogenase, the cognitive tests and electrophysiological field potential responses were recorded. Then, the hippocampus was assessed for the expression level of miR‐33‐5p using PCR. Ultimately, a histopathological study of the liver and hippocampus was carried out.

Results:

The findings revealed that except for GGT ( p = 0.1935), all liver function tests were elevated ( P = 0.0001) following BDL. The impaired inhibitory avoidance memory ( P < 0.0001) and plasticity ( P < 0.0001) and the hippocampal overexpression of miR‐33‐5p following BDL ( P <0.0001) were ameliorated by Nalx. In a qualitative histopathological study of the liver and hippocampus, Nalx attenuated the BDL‐induced changes.

Conclusions:

It is concluded that the BDL‐mediated dysfunction has a molecular, electrophysiological, and histopathological basis and might be regulated via miR‐33‐5p and opioidergic signaling. The study emphasizes the potential ameliorative role of Nalx on biliary and nervous system pathologies.

项与德拉马尼相关的新闻（医药）

2025-12-09

·文献微光

前沿综述丨结核病防治新纪元：药物研发的突破与未来展望

结核病（TB）仍为全球公共卫生挑战。虽药物研发进展，但缺全面概述。本系统梳理TB药物研发突破，评估价值与影响，为临床工作者和政策制定者提供参考。检索INFORMA医药数据库，识别1041个TB相关临床试验项目。两名研究人员独立筛选提取数据，分歧由第三方解决。纳入标准为针对TB药物研发、包含药物机制或治疗靶点详细描述、干预性研究。排除关键信息缺失、数据不完整或非干预性研究设计。采用描述性统计方法总结试验特征，可视化呈现数据分布。 1990至2025年间，TB相关临床试验数量显著增加，2018至2023年间达到高峰。中国和南非在研究活动中贡献突出，而美国和英国完成了大量已结题的试验。尽管不断有新型药物出现，但传统核心药物仍然主导着研发方向。贝达喹啉的发展尤其迅速，这得益于卫生政策的大力支持。学术机构是TB试验的主要资助者，亚洲和非洲的研究活跃度较高。但全球研究资源分布不均衡，凸显了建立更完善的协作机制的必要性，以促进健康公平与创新。本研究系统梳理了TB药物研发最新突破，揭示了全球临床试验现状与持续面临的挑战。为了实现终结TB的目标，需要持续投入科研创新、公平分配资源，并保持坚定的政治承诺。通过全球协同努力，TB防治的新纪元指日可待。为何开展本研究？🧧 TB是全球重大健康威胁，耐药病例增多，治疗效率与可及性存在缺口。新型药物如贝达喹啉和德拉马尼虽取得进展，但全球TB临床试验格局缺乏系统综述。本研究系统评估1990至2025年间的1041项TB临床试验，旨在识别重大突破、认清资源差异，并评估新疗法的科学价值与全球影响。研究获得哪些发现？🧧 中国（224项）和南非（216项）的试验数量领先，而美国和英国在已完成研究中占据主导。传统药物如异烟肼和利福平仍广泛使用，贝达喹啉的试验数量（78项）因政策支持而增加。多数试验由学术机构资助，产业界参与有限。儿童和女性等弱势群体在试验中的代表性不足。WHO2018年MDR-TB指南等政策转变加速了药物研发进程。全球资源分配不均，需加强国际合作、公平融资和包容性试验设计，以实现终结TB的目标。🦊结核病临床试验概览🦊 📝图1A展示了1990至2025年TB临床试验的时间趋势。2000年后，早期阶段试验（I期和II期）增加，2018-2023年达峰值。IV期试验2017年后增长。图1B显示过渡期试验占比较低。图1C表明试验活动全球分布不均，中国（224项）和南非（216项）领先，但乌干达和坦桑尼亚的“中止”试验多。图1D显示“已完成”试验主导，但“中止”（113项）和“关闭”（67项）试验表明资源分配效率低。 📝图1E显示，传统药物如异烟肼和利福平在研发中仍占主导，贝达喹啉增长迅速，使用频率与乙胺丁醇持平。学术机构是主要资助方（499项），政府（164项）和其他药企（161项）次之。大型制药公司仅资助52项，可能因其偏好高回报领域。非营利机构（47项）和协作组织（87项）在填补研究空白方面贡献显著，凸显公益研究的重要性（图1F）。 📝区域分析显示，亚洲（478项）和非洲（311项）试验活跃度领先，美洲（200项）和欧洲（182项）次之。南美（68项）和东欧（61项）相对落后，其他地区如加勒比/中美洲（23项）、西亚/中东（17项）和澳大利亚/大洋洲（14项）投入较低，反映出区域能力建设与政策参与不足（图1G）。 🦊全球结核病临床试验的作用机制与发展趋势🦊 📝表1总结了抗TB药物的主要作用机制及对应临床试验数量，展示了TB治疗领域的发展方向与战略。传统药物异烟肼（182项试验）和利福平（132项试验）研发数量领先，体现其基础地位与广泛应用。新型药物贝达喹啉（78项试验）和德拉马尼（42项试验）通过抑制ATP合成酶和细胞壁合成，呈现出显著增长态势，这反映了全球MDR-TB蔓延及防控力度的加强，也显示了药物创新在应对耐药性挑战中的作用。其他如天然产物（29项试验）和BCG（28项试验）等领域的试验数量较少。尽管传统药物仍主导TB研发，但新型化合物和免疫调节剂的出现标志着治疗策略向多元化转型。这一转变受科学进步、公共卫生政策、资源分配及市场力量推动。例如，RNA和蛋白质合成抑制剂的试验较多，表明对核心细菌代谢通路的研发关注持续。而DNA合成抑制剂和免疫调节剂的研发相对滞后，需增加投入应对多维挑战。 🔹总体而言，抗TB药物的多样性为优化防控策略提供指引，未来应聚焦新药与免疫疗法的协同，加强资源整合与政策支持，解决耐药性和疫苗效力问题。🦊三种新型抗结核药物的研发趋势：创新驱动与政策激励的双重影响🦊 ➡️图2展示了2005年以来贝达喹啉、德拉马尼和普托马尼的研发趋势。早期（2005-2012年），试验较少，可能由于基础研究不足。2013年后，贝达喹啉与德拉马尼的研发加速，反映出全球TB政策变化和市场需求增加。2023年，贝达喹啉（14项试验）和德拉马尼（9项试验）达到峰值，可能是应对新型耐药菌株。普托马尼的研发则保持平稳，暗示其潜力尚未完全发挥。总体而言，数据揭示了科学创新与政策干预在抗TB药物研发中的双重作用，为未来研究方向与资源分配提供参考。 🦊三种新型抗结核药物相关试验的国家与机构分布🦊 🔸全球对贝达喹啉、德拉马尼和普托马尼的研发活动分析显示，自2015年起，其临床试验数量大幅增加。这与加强的国际TB防治政策和资金投入有关。 🔹贝达喹啉的研发主要集中在中国、印度和南非，而德拉马尼和普托马尼的活跃地区为秘鲁、美国和南非（图3A–C）。学术机构、政府和非营利组织的参与度上升，反映出多方合作在药物创新中的重要性（图3D–F）。2020年后的全球疫情虽造成干扰，但相关研究活动仍保持增长，特别是贝达喹啉和普托马尼的临床试验增加，显示出对新型耐药TB治疗方案的迫切需求。 🦊三种新型抗结核药物相关试验的阶段与完成状态🦊 ➡️本研究分析2005至2025年间贝达喹啉、德拉马尼和普托马尼的临床研发情况，重点关注试验阶段与状态。研究发现，三种药物的临床试验活动均在2020年后加速，其中II期试验为主。 🔹贝达喹啉自2009年在II期试验中活跃，2023年达7项峰值，研发进程因全球对新抗TB药物需求加快。德拉马尼2023年快速增长，II期试验达7项（图4A-C），已完成试验16项，转化效率高。 🔹普托马尼则稳健发展，2023年开放状态试验3项，显示持续关注，可能成为联合疗法关键候选药物（图4D-F）。 🦊三种新型抗结核药物试验的受试者人口特征分析🦊 本研究分析了2005至2025年间贝达喹啉、德拉马尼和普托马尼的临床试验受试者的人口特征，发现性别和年龄代表性存在显著差异。跨性别研究占主导，如2023年贝达喹啉有13项试验同时纳入男女受试者（图5A-C），而针对特定性别的试验尤其是女性受试者研究较少，每年不超过1项。年龄方面，试验主要集中在成年人，如2023年德拉马尼的成人试验占当年试验总量的56%（图5D-F）。总体而言，这三种药物的临床试验对女性、儿童及老年群体的纳入不足，需要更具包容性的研究设计，以关注弱势和代表性不足的人群。

2025-12-04

·威斯克生物医药

结核新药在《世界肺部健康大会》报道，受全球瞩目

2025年世界肺部健康大会在丹麦哥本哈根举行，由国际防痨与肺部疾病联合会（UNION）主办，汇聚了来自全球150多个国家的4000余名专家和学者，是全球结核病及肺部疾病领域技术交流与成果展示的核心平台。期间结核病新工具与新方案研发专题引发广泛关注。世界卫生组织（WHO）与比尔及梅琳达·盖茨基金会（BMGF）联合主办的边会，邀请来自结核病临床试验网络与防治机构的专家，分别围绕新型治疗组合、疗程缩短策略、关键药物优化、疫苗研发突破以及全球新药研发管线等核心议题作了系统报告。其中，国家传染病医学中心主任、复旦大学附属华山医院感染科主任张文宏教授在开场主题报告中介绍了中国自主创新结核药物WX-081、JDB0131的研发进展，系统地向全球同行展现了中国在耐药结核病治疗领域的创新突破。报告指出，JDB0131在临床前及临床Ⅰ期、Ⅱa期研究中均显示出良好的疗效、优异的肺部药物浓度，以及良好的安全性与药代动力学特征，且在多个研究阶段均未观察到心脏毒性。目前其与德拉马尼的对照研究在威斯克生物推动下开展Ⅱb期临床研究，计划于2026年开展Ⅲ期临床试验。大会期间，中国疾控中心、国家传染病医学中心、北京胸科医院等多个结核防治机构现场参与了大会并进行了交流。以上内容来源于：公众号“北京胸科医院”、“感染在线InfectionOnline”、“结核那些事儿” BIOPHARMA 微信号｜WESTVAC 官网｜www.westvacpharma.com

2025-12-04

·北京医学感染与传染研究

抗菌化疗杂志 80卷 7-12期、增刊2、4期

Journal of Antimicrobial Chemotherapy Volume 80, Issue 7抗菌化疗杂志 80卷 7期 https://academic.oup.com/jac/issue REVIEWS（综述） 1 The role of antimicrobial prophylaxis in brachytherapy for prostate, breast and gynaecological cancer: a narrative review 抗生素预防用药在前列腺、乳腺及妇科癌症近距离治疗中的作用：叙述性综述 Konstantinos Alexakis and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1753–1771, 2 To be or not to be: the non-antimicrobial properties of common antimicrobials 生存还是毁灭：常见抗菌药物的非抗菌特性 Shivakumar Narayanan and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1772–1783, SYSTEMATIC REVIEWS（系统综述） 3 Antibiotic-induced Bartter-like syndrome: a systematic review 抗生素诱发的巴特综合征样表现：系统综述 Megha Priyadarshi and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1784–1791, 4 Liposomal amphotericin B prophylaxis in paediatrics: a systematic review 两性霉素B脂质体预防性用药在儿科中的应用：系统综述 Emma V Thorley and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1792–1802, ORIGINAL RESEARCH（论著） 5 Antibiotic use attributable to RSV infections during infancy—an international prospective birth cohort study 婴儿期呼吸道合胞病毒感染所致抗生素使用情况——一项国际前瞻性出生队列研究 Sarah F Hak and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1803–1812, 6 Plasmodium falciparum isolates: ex vivo drug response 恶性疟原虫分离株：体外药物反应 Edem Adika and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1813–1822, 7 Impact of hypoalbuminemia on patients receiving ertapenem combination therapy for methicillin-susceptible Staphylococcus aureus bacteraemia 低白蛋白血症对接受厄他培南联合疗法治疗甲氧西林敏感金黄色葡萄球菌菌血症患者的影响 Sunish Shah and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1823–1827, 8 Exploring community pharmacy professionals and general practitioners’ views on primary care communication and pathways to access antibiotics in England 探究英国社区药房专业人员和全科医生对初级保健沟通及获取抗生素途径的看法 Ming Xuan Lee and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1828–1836, 9 Decline of antimicrobial resistance in Pseudomonas aeruginosa bacteraemia following the COVID-19 pandemic: a longitudinal observational study 新冠疫情后铜绿假单胞菌菌血症抗菌药物耐药性的下降：一项纵向观察研究 Yulia Butscheid and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1837–1848, 10 Selected comorbidities and the probability of ART switch in PWH with undetectable HIV-RNA: a retrospective analysis in Italy 意大利HIV感染者（HIV-RNA不可检测）特定合并症与抗逆转录病毒药物转换概率：一项回顾性分析 Alessandro Cozzi-Lepri and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1849–1859, 11 Model-based translation of the PKPD-relationship for linezolid and vancomycin on methicillin-resistant Staphylococcus aureus: from in vitro time–kill experiments to a mouse pneumonia model 基于模型转化利奈唑胺和万古霉素对甲氧西林耐药金黄色葡萄球菌的药代动力学-药效学关系：从体外时间杀菌实验到小鼠肺炎模型 Diego Vera-Yunca and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1860–1868, 12 Inner-mitochondrial membrane protein PfMPV17 is linked to P. falciparum in vitro resistance to the indoloquinolizidine alkaloid alstonine 线粒体内膜蛋白PfMPV17与恶性疟原虫对吲哚醌啉生物碱阿尔斯通宁的体外耐药性相关 J R Macdonald and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1869–1877, 13 Efficacy and tolerability of the combination of minocycline and metronidazole for macrolide-resistant Mycoplasma genitalium 米诺环素与甲硝唑联合治疗大环内酯类耐药生殖支原体感染的疗效和耐受性 Kay Htaik and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1878–1884, 14 Early use of the novel antifungal rezafungin: a case series and literature review 新型抗真菌药物瑞扎芬净的早期使用：病例系列报道及文献综述 H C Davidson and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1885–1892, 15 Optimal dosing of amoxicillin in obese and post-gastric bypass patients using a population pharmacokinetics-pharmacodynamics model approach 基于群体药代动力学-药效学模型方法确定阿莫西林在肥胖和胃旁路术后患者中的最佳剂量 Gisela Myrian de Lima Leite Dalla Rosa and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1893–1901, 16 Decreasing antimicrobial resistance in representative UK livestock species was associated with reduced total sales of antimicrobials in the last decade 过去十年，英国代表性家畜物种抗菌药物耐药性下降与抗菌药物总销量减少相关 Aliya El Nagar and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1902–1906, 17 An improved multiplex RT–quantitative PCR assay can reveal sex-specific activity of transmission-blocking drugs on ex vivo gametocytes from Plasmodium falciparum asymptomatic infections 一种改进的多重逆转录定量聚合酶链反应检测法可揭示性特异性抗疟疾传播阻断药物对恶性疟原虫无症状感染体外配子体活性的影响 Mariagrazia Ciardo and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1907–1914, 18 Population pharmacokinetics and thrombocytopenia risk assessment of linezolid in liver transplant recipients 利奈唑胺在肝移植受者中的群体药代动力学及血小板减少症风险评估 Xiaoping Shi and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1915–1925, 19 Rapid susceptibility testing on urine for antimicrobial stewardship in general practice 全科实践中的尿液快速药敏试验助力抗菌药物管理 Patrick D J Sturm and Tanja Schülin Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1926–1932, 20 Efficacy of linezolid in monotherapy q12h versus q8h versus combined with daptomycin in the treatment of experimental endocarditis caused by methicillin-resistant and glycopeptide-intermediate Staphylococcus aureus strains 利奈唑胺单药治疗每12小时一次与每8小时一次，以及与达托霉素联合治疗甲氧西林耐药和糖肽中介金黄色葡萄球菌菌株所致实验性心内膜炎的疗效 María-Alexandra Cañas and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1933–1941, 21 In vitro activity of NOSO-502, a novel-action antimicrobial, against clinical strains of Enterobacterales including MDR strains 新型作用机制抗菌药物NOSO-502对包括多重耐药菌株在内的肠杆菌科临床菌株的体外活性 Marie L G Attwood and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1942–1946, 22 Antibacterial activity of propylene glycol against Staphylococcus aureus and Staphylococcus epidermidis in neutral and mild acidic conditions 中性及弱酸性条件下，丙二醇对金黄色葡萄球菌和表皮葡萄球菌的抗菌活性 Nadiia Mosiichuk and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1947–1950, 23 Molecular characteristics of chromosome-mediated colistin resistance in foodborne Salmonella isolates in China 中国食源性沙门氏菌分离株染色体介导的多粘菌素耐药性的分子特征 Zeqiang Zhan and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1951–1963, 24 High azole non-wild type rates and nosocomial microsatellite typing aggregation of Wickerhamomyces anomalus in China according to a 12-year multicenter surveillance study 根据一项为期12年的多中心监测研究，中国异常威克汉姆酵母属唑类非野生型率高且医院内微卫星分型聚集 Zhengyu Luo and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1964–1971, 25 Repurposing antimalarials: pyrimethamine exhibits superior in vitro activity to metronidazole against Gardnerella while sparing Lactobacillus 抗疟药物再利用：乙胺嘧啶对加德纳菌的体外活性优于甲硝唑，且对乳酸杆菌无影响 Aliona S Rosca and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1972–1979, 26 Clinical characteristics and risk factors of tigecycline-induced acute pancreatitis in kidney transplant recipients: a retrospective study 肾移植受者替加环素诱发急性胰腺炎的临床特征及危险因素：一项回顾性研究 Lijuan Feng and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1980–1987, 27 Genomic characteristics of the multiresistant Acinetobacter baumannii global clone 1 reference strain A297/RUH875 多重耐药鲍曼不动杆菌全球克隆1型参考菌株A297/RUH875的基因组特征 Jonathan Koong and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1988–1992, 28 Comparison of a modified broth microdilution Sensititre™ SLOMYCOI assay with the CLSI-recommended agar disk elution method for antimicrobial susceptibility testing of Mycobacterium haemophilum 改良肉汤微量稀释Sensititre™ SLOMYCOI检测法与CLSI推荐的琼脂稀释法对嗜血杆菌属抗菌药物敏感性检测的比较 Doris Hillemann and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1993–1996, 29 Reversal of phenotypic resistance in multi-drug resistant carbapenemase-producing K. pneumoniae clinical isolates due to in vitro synergistic interactions between bacteriophages and antibiotics at clinically achievable concentrations 由于细菌噬菌体和抗生素在临床可达到浓度下的体外协同作用，多重耐药碳青霉烯酶产生肺炎克雷伯菌临床分离株的表型耐药性发生逆转 Paschalis Paranos and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1997–2006, 30 Antibiotic resistance and population structure of Staphylococcus epidermidis from prosthetic joint infections in Sweden and France 瑞典和法国假体关节感染表皮葡萄球菌的抗生素耐药性和群体结构 Sofie M Edslev and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 2007–2015, 31 Lines on the line: evaluating the impact of antibiotic lock therapy versus catheter removal in the management of central vascular catheter infections 抗生素锁疗法与导管拔除术治疗中心血管导管感染的影响评估 Nischal Ranganath and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 2016–2024, 32 Real-time FT-IR typing of Klebsiella pneumoniae: a flexible and rapid approach for outbreak detection and infection control 肺炎克雷伯菌实时傅里叶变换红外分型：一种灵活快速的暴发检测和感染控制方法 Ana Beatriz Gonçalves and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 2025–2031, 33 Antibiotic stress affects the secretion and physicochemical features of extracellular vesicles produced by Helicobacter pylori 抗生素压力影响幽门螺杆菌产生的细胞外囊泡的分泌和物理化学特性 Paweł Krzyżek and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 2032–2043, 34 A novel azithromycin resistance mutation in Mycoplasma genitalium induced in vitro 生殖支原体体外诱导产生的新型阿奇霉素耐药突变 Teck-Phui Chua and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 2044–2050, RESEARCH LETTERS（研究信函） 35 Posaconazole dosing of enteral formulations in infants and young children to achieve therapeutic concentrations 婴儿和幼儿肠内制剂泊沙康唑的给药剂量以达到治疗浓度 Jeffrey Harrington and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 2051–2053, 36 Antimony used as rescue therapy in a kidney transplant recipient unresponsive to liposomal amphotericin B for chronic visceral leishmaniasis 两性霉素B脂质体治疗慢性内脏利什曼病无效的肾移植受者中使用锑剂作为挽救疗法 Natacha Mrozek and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 2053–2056, 37 Is cefazolin an option for treatment of staphylococcal endogenous endophthalmitis? 头孢唑林是否可用于治疗葡萄球菌性内源性眼内炎？ Alexandra Morin and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 2057–2058, LETTER TO THE EDITOR（致编辑的信） 38 Use of teicoplanin monotherapy for the treatment of enterococcal infective endocarditis: a retrospective and comparative study at a referral centre—a counterpoint 单用替考拉宁治疗肠球菌感染性心内膜炎：一家转诊中心的回顾性和比较研究——反驳观点 Miguel Villamarín and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 2059–2060, Journal of Antimicrobial Chemotherapy Volume 80, Issue 8 抗菌化疗杂志 80卷 8期 https://academic.oup.com/jac/issue Review(综述) 1 World Health Organisation’s Bacterial Pathogen Priority List (BPPL) 2017 and BPPL 2024 to combat global antimicrobial resistance crisis: ‘challenges and opportunities’ 世界卫生组织2017年和2024年用以应对全球抗菌药物耐药性危机的细菌病原体优先名单（BPPL）：“挑战与机遇” Vazhayil Hari Krishnaprasad and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2061–2069 Original Research(论著) 2 Aztreonam/avibactam activity against Enterobacterales from European medical centres: summary of 5years of surveillance prior to approval for clinical use (2019–2023) 氨曲南/阿维巴坦对欧洲医疗中心肠杆菌科细菌的活性：临床批准前5年（2019-2023年）监测总结 Helio S Sader and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2070–2079 3 High feasibility of salivary therapeutic drug monitoring in linezolid, but lower feasibility in tedizolid: a single-dose study in healthy subjects and a monocentric prospective exploratory study in patients who received linezolid 利奈唑胺唾液治疗药物监测可行性高，但替地唑胺可行性较低：一项健康受试者单剂量研究和一项接受利奈唑胺患者单中心前瞻性探索性研究 Hitoshi Kawasuji and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2080–2091 4 Establishment and validation of downsized hollow-fibre infection model and pharmacokinetics/pharmacodynamics analysis of VAN on Enterococcus faecium 缩小版中空纤维感染模型的建立与验证及万古霉素对粪肠球菌的药代动力学/药效学分析 Yukitaka Hayashi and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2092–2099 5 Four-month clofazimine regimen for susceptible pulmonary TB: a randomized clinical trial 为期4个月的氯法齐明方案治疗敏感型肺结核：一项随机临床试验 Nusrat Shafiq and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2100–2108 6 An ex vivo model to determine transmembrane clearance of antimicrobials during continuous renal replacement therapy 用于确定连续性肾脏替代治疗期间抗菌药物跨膜清除率的体外模型 Cole McGrath and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2109–2116 7 Optimization and improvement of the disc diffusion method for mucoid Pseudomonas aeruginosa 黏液型铜绿假单胞菌纸片扩散法的优化与改进 Aixin Wang and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2117–2125 8 HIV-1 drug resistance among people living with HIV receiving dolutegravir-based anti-retroviral regimens in Uganda: a national laboratory-based survey using remnant viral load samples, 2022 乌干达接受基于多替拉韦抗逆转录病毒方案的HIV感染者中HIV-1耐药性情况：2022年一项基于国家实验室使用剩余病毒载量样本的调查 Christine Watera and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2126–2134 9 Population pharmacokinetics of weight-based compared with fixed dosing of CAP256V2LS, a broadly neutralizing antibody for HIV prevention in women 与固定剂量相比，基于体重给药的CAP256V2LS（一种用于女性HIV预防的广谱中和抗体）群体药代动力学研究 Sharana Mahomed and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2135–2144 10 Gut microbiota and weight gain in people with HIV on integrase inhibitors: a five-year longitudinal study 接受整合酶抑制剂治疗的HIV感染者肠道微生物群与体重增加情况：一项为期五年的纵向研究 Javier García-Abellán and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2145–2157 11 Development of a ribavirin dosing regimen in transplant recipients with chronic hepatitis E virus infection: a population pharmacokinetic and -dynamic model 慢性戊型肝炎病毒感染移植受者利巴韦林给药方案的开发：一项群体药代动力学和药效学模型研究 Midas B Mulder and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2158–2168 12 Effectiveness and predictors of treatment discontinuation of long-acting cabotegravir/rilpivirine in virologically suppressed people with HIV: real-life data from the Icona Cohort 长效卡博特韦/利匹韦林在病毒受抑制的HIV感染者中的治疗中断有效性和预测因素：来自Icona队列的现实数据 Roberta Gagliardini and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2169–2178 13 Five-days-on-two-days-off (FOTO) versus daily bictegravir/emtricitabine/tenofovir alafenamide in virologically suppressed people with HIV: a pilot randomized clinical trial 病毒受抑制的HIV感染者中，5天用药2天停药（FOTO）方案与每日比克替拉韦/恩曲他滨/丙酚替诺福韦方案的对比：一项初步随机临床试验 Hsin-Yun Sun and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2179–2186 14 Reliability of disc diffusion testing and molecular epidemiology of penicillin-susceptible Staphylococcus aureus bacteraemia 青霉素敏感金黄色葡萄球菌菌血症的纸片扩散试验可靠性和分子流行病学研究 Pernilla Kihlberg and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2187–2193 15 Outcomes of ceftriaxone 2g versus 1g daily in hospitalized patients with pneumonia: a nationwide retrospective cohort study 住院肺炎患者每日头孢曲松2克与1克疗效对比：一项全国性回顾性队列研究 Jumpei Taniguchi and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2194–2202 16 Oleanolic acid derivative bardoxolone combats multidrug-resistant Staphylococcus aureus by destroying cell membrane and pyruvate metabolism pathway 齐墩果酸衍生物巴多昔隆通过破坏细胞膜和丙酮酸代谢途径对抗多重耐药金黄色葡萄球菌 Yun-Dan Zheng and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2203–2213 17 Evaluation of amoxicillin and benzylpenicillin therapy in early-onset neonatal sepsis: a pharmacometric external validation and simulation study 阿莫西林和苄青霉素治疗早期新生儿败血症的评估：一项药效计量学外部验证和模拟研究 Tom C Zwart and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2214–2225 18 48Week body composition changes in persons with HIV switching to dolutegravir plus lamivudine: a planned subanalysis of the DOLAM randomized clinical trial HIV感染者换用多替拉韦加拉米夫定治疗48周身体成分变化：DOLAM随机临床试验的计划子分析 Elisa de Lazzari and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2226–2233 19 The impact of inter-infection time on antimicrobial resistance profiles in women with multiple urinary tract infections over time 多次尿路感染女性患者感染间隔时间对抗菌药物耐药性特征的影响 Trenton Honda and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2234–2240 20 Development and evaluation of a novel rapid immunochromatographic assay for the detection of DHA-producing Enterobacterales 一种检测产DHA肠杆菌科细菌的新型快速免疫层析法的开发与评估 Christian Moguet and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2241–2246 21 Enterococcus faecium bacteraemia: a multicentre observational study focused on risk factors for clinical and microbiological outcomes 粪肠球菌菌血症：一项关注临床和微生物学结局风险因素的多中心观察性研究 Matteo Rinaldi and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2247–2256 22 Indolocarbazoles as host-directed therapeutics against intracellular infections by methicillin-resistant Staphylococcus aureus 靛红咔唑类化合物作为宿主导向疗法对抗甲氧西林耐药金黄色葡萄球菌细胞内感染 Robin H G A van den Biggelaar and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2257–2268 23 Clinical validation of antimicrobial dosing regimens for continuous renal replacement therapy based on an ex vivo dosing algorithm 基于体外给药算法的连续性肾脏替代治疗抗菌药物给药方案的临床验证 Christina Koenig and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2269–2279 24 Novel integrative and conjugative elements carrying cfr(B) and cfr(C) linezolid resistance genes in Clostridioides difficile isolates from calves, Italy 意大利牛犊艰难梭菌分离株中携带cfr(B)和cfr(C)利奈唑胺耐药基因的新型整合性和接合性元件 Andrea Brenciani and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2280–2284 25 Characterization of Carbapenemase-producing Enterobacterales isolated from patients returning from Sub-Saharan Africa, France, 2015–2022 2015-2022年从撒哈拉以南非洲返回的法国患者中分离出的产碳青霉烯酶肠杆菌科细菌的特征 Corentin Poignon and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2285–2294 26 Penicillin-susceptible ST398 with strong biofilm-forming ability poses a significant threat to osteoarticular infections 具有强生物膜形成能力的青霉素敏感ST398型对骨关节感染构成重大威胁 Ye Jin and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2295–2304 27 Cardiac safety of bedaquiline, delamanid and moxifloxacin co-administered with or without varying doses of sutezolid or delpazolid for the treatment of drug-susceptible TB 贝达喹啉、德拉马尼和莫西沙星与不同剂量苏特唑利或德帕唑利联合用药治疗药物敏感型肺结核的心脏安全性 Simon E Koele and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2305–2313 28 Comparison of ceftolozane/tazobactam and meropenem in treating bloodstream infections caused by extended-spectrum β-lactamase-producing Enterobacterales: a single-centre, retrospective, real-world study 头孢托唑坦/他唑巴坦与美罗培南治疗产超广谱β-内酰胺酶肠杆菌科细菌所致血流感染的对比：一项单中心回顾性现实研究 Dimitrios Basoulis and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2314–2322 Research Letters(研究信件) 29 Dalbavancin as chronic suppressive therapy in a patient undergoing monthly apheresis: a case report with therapeutic drug monitoring 达巴万星作为每月进行血浆置换术患者的长期抑制治疗：一项带治疗药物监测的病例报告 Carlo Pallotto and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2323–2324 30 A novel methicillin-resistant Staphylococcus aureus lineage (ST4174) with an uncharacterized SCCmec variant identified in Korean pigs 韩国猪体内发现的一种带有未表征SCCmec变体的新型甲氧西林耐药金黄色葡萄球菌谱系（ST4174） Hyeonwoo Cho and Kun Taek Park Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2325–2326 31 Time fixes everything, but not always: 10years of persistent PI mutations in the absence of pharmacological pressure—a case report 时间能治愈一切，但并非总是如此：无药物压力下持续10年的蛋白酶抑制剂突变——一例病例报告 Layla Pagnucco and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2327–2330 32 Carbapenem resistance in Escherichia marmotae: characterization of IncL plasmids carrying blaOXA-48 土拨鼠埃希菌的碳青霉烯耐药性：携带blaOXA-48的IncL质粒特征 Astrid Rasmussen and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2330–2331 Letters to the Editor(致编辑的信) 33 Comment on: Clinical outcomes and the impact of treatment modalities in children with carbapenem-resistant Enterobacteriaceae bloodstream infections: a retrospective cohort study from a tertiary university hospital 述评：产碳青霉烯酶肠杆菌科细菌血流感染患儿的临床预后和治疗方式的影响：一项来自三级大学医院的回顾性队列研究 Jianjun Li and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Page 2332 34 Clinical outcomes and the impact of treatment modalities in children with carbapenem-resistant Enterobacteriaceae bloodstream infections: a retrospective cohort study from a Tertiary University Hospital—right to reply—author’s response 产碳青霉烯酶肠杆菌科细菌血流感染患儿的临床预后和治疗方式的影响：一项来自三级大学医院的回顾性队列研究——作者回复 Gulhadiye Avcu Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2332–2333 Corrections(更正) 35 Correction to: Sofosbuvir as post-exposure prophylaxis for yellow fever–associated viscerotropic disease (YEL-AVD) 更正：索非布韦作为黄热病相关内脏热带病（YEL-AVD）暴露后预防用药 Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Page 2334 36 Correction to: Pandemic human-associated extended-spectrum β-lactamase-producing Escherichia coli lineages of ST38, ST131 and ST141 identified in Viennese dogs 更正：维也纳犬体内发现与人相关的大流行性产超广谱β-内酰胺酶大肠杆菌ST38、ST131和ST141谱系 Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Page 2335 37 Correction to: GP or ChatGPT? Ability of large language models (LLMs) to support general practitioners when prescribing antibiotics 更正：全科医生还是ChatGPT？大型语言模型（LLM）在全科医生开具抗生素处方时的辅助能力 Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Page 2336 Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_2 抗菌化疗杂志 80卷增刊2期 https://academic.oup.com/jac/issue SUPPLEMENT (补充) CANWARD 2007-23 加拿大抗感染耐药监测项目（CANWARD）2007-2023年数据/报告 Foreword(前言) 1 The CANWARD studies: Canadian Antimicrobial Resistance Alliance (CARA) Canadian Hospital Ward Antibiotic Resistance Surveillance collection 加拿大抗感染耐药监测项目研究：加拿大抗微生物耐药联盟（CARA）加拿大医院病房耐药性监测数据集 James C Hurley and Jean-Yves Madec Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_2, September 2025, Page ii1 Supplement Papers(补充论文) 2 Seventeen years of the CANWARD study (2007–23) 加拿大抗感染耐药监测项目研究17年（2007-2023年） George G Zhanel and Heather J Adam Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_2, September 2025, Pages ii2–ii4 3 Gram-positive pathogens from Canadian hospitals: 17years of results from the CANWARD study (2007–23) 来自加拿大医院的革兰氏阳性病原体：加拿大抗感染耐药监测项目研究的17年结果（2007-2023） George G Zhanel and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_2, September 2025, Pages ii5–ii14 4 Gram-negative pathogens from Canadian hospitals: 17 years of results from the CANWARD study (2007–23) 来自加拿大医院的革兰氏阴性病原体：加拿大抗感染耐药监测项目研究的17年结果（2007-2023） George G Zhanel and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_2, September 2025, Pages ii15–ii26 5 Characterization of methicillin-resistant Staphylococcus aureus in Canadian hospitals: 17 years of the CANWARD study (2007–23) 加拿大医院耐甲氧西林金黄色葡萄球菌的特征：加拿大抗感染耐药监测项目研究的17年（2007-2023） Anissa Brahami and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_2, September 2025, Pages ii27–ii34 6 Comparison of antimicrobial resistance and serotype patterns in Streptococcus pneumoniae from blood cultures and respiratory specimens in Canadian hospitals from the CANWARD study (2007–23) 加拿大抗感染耐药监测项目研究中加拿大医院血液培养和呼吸道标本中肺炎链球菌抗微生物药物耐药性和血清型的比较（2007-23） Heather J Adam and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_2, September 2025, Pages ii35–ii44 7 Increasing rates of ESBL-producing Escherichia coli and Klebsiella pneumoniae in Canadian Hospitals: 17 years of the CANWARD study, 2007–23 加拿大医院中产生ESBL的大肠杆菌和肺炎克雷伯菌的比率增加：加拿大抗感染耐药监测项目研究17年，2007-2023 Philippe Lagacé-Wiens and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_2, September 2025, Pages ii45–ii53 8 Characterization of ertapenem-resistant Enterobacterales in Canadian hospitals: 17 years of the CANWARD study (2007–23) 加拿大医院耐厄他培宁肠杆菌的特征：17年的加拿大抗感染耐药监测项目研究（2007-23） Laura F Mataseje and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_2, September 2025, Pages ii54–ii61 9 Characterization of carbapenem-resistant Pseudomonas aeruginosa in Canadian hospitals: 6years of the CANWARD study (2018–23) 加拿大医院耐碳青霉烯假单胞菌的特征：6年的加拿大抗感染耐药监测项目研究（2018-23） Melissa McCracken and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_2, September 2025, Pages ii62–ii71 10 Distribution and antimicrobial susceptibility profile of pathogens recovered from the bloodstream of Canadian patients: results from the CANWARD study (2007–23) 加拿大患者血液中病原菌的分布和药敏特征：来自加拿大抗感染耐药监测项目研究（2007-23）的结果 Andrew Walkty and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_2, September 2025, Pages ii72–ii82 Journal of Antimicrobial Chemotherapy Volume 80, Issue 9抗菌化疗杂志 80卷 9期 https://academic.oup.com/jac/issue VIEWPOINT（观点） 1 Classifying patients with invasive fungal disease: towards a unified case definition? 侵袭性真菌病患者分类：能否达成统一的病例定义？ Mehmet Ergün and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2337–2343, SYSTEMATIC REVIEW（系统综述） 2 Efficacy and safety of earlier switching to an oral antibiotic therapy for the treatment of Gram-positive bloodstream infections: a systematic review and meta-analysis 早期转换为口服抗生素治疗革兰氏阳性菌血流感染的疗效和安全性：一项系统综述和荟萃分析 ZhaoYi Tan and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2344–2360, ORIGINAL RESEARCH（论著） 3 Determination of epidemiological cut-off values for Narasin, Salinomycin, Lasalocid and Monensin in Enterococcus faecium 屎肠球菌中那拉霉素、盐霉素、拉沙洛西钠和莫能菌素流行病学临界值的测定 Maria Laura Ferrando and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2361–2368, 4 Persistence of CXCR4-tropic virus in people living with four-class drug-resistant HIV and its clinical impact in the modern antiretroviral era 四类耐药HIV感染者体内CXCR4嗜性病毒的持续存在及其在现代抗逆转录病毒治疗时代的临床影响 Rebecka Papaioannu Borjesson and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2369–2374, 5 Hypertension and blood pressure changes with dolutegravir or comparator antiretroviral therapy in randomized trials through 96 weeks 随机试验中96周内使用多替拉韦或对照抗逆转录病毒疗法对高血压和血压变化的影响 Parul Patel and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2375–2383, 6 Comparative analysis of lipid profile changes in treatment-naïve people living with HIV on INSTI-based single-tablet regimens, BIC/FTC/TAF and DTG/3TC: real-world evidence from South Korea 基于整合酶抑制剂的单片复方制剂BIC/FTC/TAF和DTG/3TC在韩国初治HIV感染者中血脂谱变化的比较分析：来自现实世界的证据 So Yun Lim and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2384–2390, 7 A novel multilocus sequence typing scheme for Morganella spp.: population structure and introduction of quantitative metric for standardization of MLST scheme 摩根氏菌属的一种新型多位点序列分型方案：群体结构及引入用于标准化多位点序列分型方案的定量度量标准 Aymeric Jacquemin and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2391–2398, 8 Genomic characterization of multidrug-resistant extended-spectrum β-lactamase-producing Vibrio cholerae O1 strains from 2022 cholera outbreak in Kenya 2022年肯尼亚霍乱疫情中产超广谱β-内酰胺酶的多重耐药霍乱弧菌O1株的基因组特征 Diana Imoli and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2399–2407, 9 Impact of empiric anti-VRE therapy on survival in vancomycin-resistant enterococcal bloodstream infection 经验性抗万古霉素耐药肠球菌治疗对万古霉素耐药肠球菌血流感染患者生存率的影响 Tao-Hung Ou and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2408–2416, 10 Safety of topical tobramycin powder during operative treatment of fractures 骨折手术中使用局部妥布霉素粉末的安全性 Gregory M Schrank and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2417–2420, 11 Trimethoprim/sulfamethoxazole and risk of haemophagocytic lymphohistiocytosis (HLH): a literature review and disproportionality analysis using individual case safety reports from FAERS 复方磺胺甲恶唑与噬血细胞性淋巴组织细胞增多症（HLH）的风险：基于FAERS数据库个案安全报告的文献综述和比例失衡分析 Rinko Lau and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2421–2427, 12 Highly drug-resistant Vibrio cholerae harbouring blaPER-7 isolated from travellers returning to England 从返回英国的旅行者中分离出携带blaPER-7基因的高度耐药霍乱弧菌 Satheesh Nair and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2428–2432, 13 Overcoming antimicrobial resistance in Helicobacter pylori: the roles of collateral sensitivity and biofilm dynamics 克服幽门螺杆菌的抗菌药物耐药性：附带敏感性和生物膜动态的作用 Siddharth Singh and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2433–2441, 14 Clinical and microbiological analysis of bloodstream infections by four cefiderocol-resistant and not previously exposed NDM-producing Klebsiella pneumoniae 四种未接触过但对头孢地尔耐药的产NDM肺炎克雷伯菌所致血流感染的临床和微生物学分析 Maria Mazzitelli and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2442–2446, 15 Synergistic effects of DHA27 combined with gentamicin against methicillin-resistant Staphylococcus aureus in vitro and in vivo DHA27与庆大霉素联合对耐甲氧西林金黄色葡萄球菌的体内外协同作用 Xuemin Chen and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2447–2458, 16 A multicentre study for determination of epidemiological cut-off values for Candida auris with EUCAST broth microdilution reference methodology 采用EUCAST肉汤微量稀释参考方法进行耳念珠菌流行病学临界值的多中心测定研究 Joseph Meletiadis and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2459–2465, 17 Impact of vancomycin resistance on attributable mortality among Enterococcus faecium bloodstream infections: propensity score analysis of a large, multicentre retrospective study 万古霉素耐药对屎肠球菌血流感染归因死亡率的影响：一项大型多中心回顾性研究的倾向评分分析 M Del Monte and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2466–2473, 18 Dynamics of dual CMV and EBV co-reactivation and emergence of resistance in an HSCT recipient 异基因造血干细胞移植受者中CMV和EBV双重再激活的动态变化及耐药性的出现 Martyna Pociupany and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2474–2483, 19 Antimicrobial use for the treatment of bacterial sexually transmitted infections among doxycycline post-exposure prophylaxis (DoxyPEP) users in Milan, Italy 意大利米兰多西环素暴露后预防（DoxyPEP）使用者中用于治疗细菌性性传播感染的抗菌药物使用情况 Angelo Roberto Raccagni and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2484–2486, 20 Comparing the mortality of patients with sepsis using empirical piperacillin/tazobactam and cefepime: analysis of the MIMIC-IV database 使用经验性哌拉西林/他唑巴坦和头孢吡肟的脓毒症患者死亡率比较：基于MIMIC-IV数据库的分析 Yongseop Lee and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2487–2495, 21 Transmitted drug resistance profiles among people living with HIV-1 in Henan province, China, 2024 2024年中国河南省HIV-1感染者传播耐药情况 Jinjin Liu and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2496–2502, 22 Fluctuations in copy number of the class A carbapenemase gene blaFRI appear to confer high-level carbapenem resistance A类碳青霉烯酶基因blaFRI拷贝数的波动似乎赋予了高水平碳青霉烯耐药性 Makiko Noda and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2503–2512, 23 In vitro activity of ceftobiprole plus ampicillin against Enterococcus faecalis causing infective endocarditis: phenotypic and genotypic characterization 头孢比罗联合氨苄西林对引起感染性心内膜炎的粪肠球菌的体外活性：表型和基因型特征 Clara Moretó-Castellsaguéand others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2513–2523, 24 Paradoxical interaction between dalbavancin and β-lactams against endocarditis-associated Enterococcus faecalis clinical isolates 达巴万星与β-内酰胺类药物对心内膜炎相关粪肠球菌临床分离株的矛盾相互作用 David Luque Paz and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2524–2529, 25 Comparative evaluation of broth microdilution and gradient diffusion methods in Burkholderia cepacia complex susceptibility testing: implications of transitioning to ECV-based interpretation 伯克霍尔德菌复合群药敏试验中肉汤微量稀释法和梯度扩散法的比较评估：向基于ECV解释转变的影响 Wenjie Cui and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2530–2540, 26 Strengthening antimicrobial resistance diagnostics in National Reference Laboratories across One Health in South and Southeast Asia: impact of external quality assessment and targeted follow-up 加强南亚和东南亚“同一健康”国家参考实验室的抗菌药物耐药性诊断能力：外部质量评估和针对性随访的影响 Freshwork Ayalew Abegaz and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2541–2549, RESEARCH LETTERS（研究快信） 27 TDM-guided meropenem/vaborbactam-based therapy for successful treatment of intra-abdominal and bloodstream infection caused by KPC-producing ceftazidime/avibactam-resistant Klebsiella pneumoniae in a paediatric liver transplant recipient 治疗药物监测指导下的美罗培南/瓦博巴坦疗法成功治疗儿童肝移植受者中产KPC且对头孢他啶/阿维巴坦耐药的肺炎克雷伯菌引起的腹腔和血流感染 Giovanni Mulé and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2550–2552, 28 Novel tmexC7D2-toprJ5 gene cluster and transposon Tn7759 carrying blaVIM-2 and blaOXA-10 genes in a carbapenem-resistant Pseudomonas putida from urban sewage 城市污水中碳青霉烯耐药恶臭假单胞菌中携带blaVIM-2和blaOXA-10基因的新型tmexC7D2-toprJ5基因簇和转座子Tn7759 Xinyuan Qiu and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2552–2555, 29 Characterization of multiresistance gene optrA in Bacillus subtillis from China 中国枯草芽孢杆菌中多重耐药基因optrA的特征分析 Yongliang Che and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2555–2557, 30 Genomic characterization of a multidrug-resistant Mammaliicoccus sciuri strain isolated from urine of a patient from China 从中国患者尿液中分离出的一株多重耐药马氏鼠球菌的基因组特征 Fuqiang Ye and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2558–2560, LETTERS TO THE EDITOR（致编辑的信） 31 Comment on: Isavuconazole therapeutic drug monitoring and association with adverse events 关于“艾沙康唑治疗药物监测及其与不良反应的关联”的评论 Mi Zhou and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2561–2562, 32 Comment on: Outcomes of ceftriaxone 2 g versus 1 g daily in hospitalised patients with pneumonia: a nationwide retrospective cohort study 关于“住院肺炎患者每日2克与1克头孢曲松疗效比较：一项全国性回顾性队列研究”的评论 Satoru Mitsuboshi Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Page 2563, 33 Outcomes of ceftriaxone 2 g versus 1 g daily in hospitalized patients with pneumonia: a nationwide retrospective cohort study—authors’ response 住院肺炎患者每日2克与1克头孢曲松疗效比较：一项全国性回顾性队列研究——作者回复 Jumpei Taniguchi and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2563–2564, Journal of Antimicrobial Chemotherapy Volume 80, Issue 10抗菌化疗杂志 80卷 10期 https://academic.oup.com/jac/issue REVIEWS（综述） 1 Long-acting cabotegravir and rilpivirine for the treatment of people with HIV: current landscape and challenges ahead 长效卡博特韦和利匹韦林治疗HIV感染者的现状与未来挑战 Luis Buzón-Martín and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2565–2586, 2 Systematic reviews and the Journal of Antimicrobial Chemotherapy; past, present and future. A systematic reappraisal 系统综述与《抗菌化疗杂志》：过去、现在与未来——系统再评估 James C Hurley Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2587–2596, SYSTEMATIC REVIEWS（系统综述） 3 Studying intrapulmonary pharmacokinetics for tuberculosis treatment: a systematic review of methodology 研究肺结核治疗的肺内药代动力学：方法学的系统综述 Isabella van der Feltz and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2597–2608, 4 Global prevalence of nitrofurantoin-resistant uropathogenic Escherichia coli (UPEC) in humans: a systematic review and meta-analysis 全球人类中耐呋喃妥因的尿路致病性大肠埃希菌（UPEC）流行率：系统综述与荟萃分析 Christopher Larkin and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2609–2621, ORIGINAL RESEARCH（研究论著） 5 Is ampicillin plus cephalosporins a therapeutic option for Ampicillin-Susceptible Enterococcus faecium? 氨苄青霉素联合头孢菌素是否为氨苄青霉素敏感的粪肠球菌的治疗选择？ Paula Bierge and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2622–2629, 6 Therapeutic efficacy monitoring of pyronaridine–artesunate (Pyramax®) in treating uncomplicated Plasmodium falciparum malaria in Gia Lai province, Vietnam from 2022 to 2023 2022-2023年越南嘉莱省青蒿琥酯-吡咯尼抗（Pyramax®）用于无并发症恶性疟原虫疟疾的治疗效果监测 Nguyen Van Thanh and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2630–2634, 7 Effectiveness of piperacillin/tazobactam loading dose for extended infusion dosing among patients with Gram-negative bacteraemia 哌拉西林/他唑巴坦负荷剂量用于革兰氏阴性菌血症患者延长输注给药的有效性 Savan Patel and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2635–2643, 8 Intrapulmonary concentrations of ceftobiprole high doses administered by continuous infusion in critically ill patients with community-acquired pneumonia 连续输注大剂量头孢比罗在社区获得性肺炎危重患者中的肺内浓度 Claire Roger and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2644–2653, 9 Cefixime versus benzathine penicillin G for the treatment of early syphilis—a randomized, controlled open label trial 头孢克肟与苄星青霉素G治疗早期梅毒的随机对照开放标签试验 Tamara Klementová and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2654–2658, 10 Trends in antifungal use among hospitalized patients in the USA, 2018–23 2018-2023年美国住院患者抗真菌药物使用趋势 Dallas J Smith and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2659–2664, 11 Clinical impact of the BCID2 and rapid AST VITEK® REVEALTM on antibiotic optimisation in critically ill patients with Gram-negative bloodstream infections: a quasi-experimental pre/post interventional study BCID2和快速AST VITEK® REVEALTM对革兰氏阴性菌血流感染危重患者抗生素优化的临床影响：一项准实验性前后干预研究 Louis Oudiane and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2665–2675, 12 In vitro activity of thiamphenicol against drug-susceptible and drug-resistant strains of Mycoplasma genitalium 甲砜霉素对药物敏感和耐药生殖支原体菌株的体外活性 Sofie Skovmand and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2676–2681, 13 A priori optimization of levofloxacin dose regimen based on a population pharmacokinetics model 基于群体药代动力学模型的左氧氟沙星剂量方案先验优化 Emmanuel Enard and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2682–2692, 14 Model-informed individualized administration of ceftazidime–avibactam in critically ill patients: population pharmacokinetics studies and a parametric time-to-event analysis 危重患者头孢他啶-阿维巴坦的模型知情个体化给药：群体药代动力学研究和参数时间事件分析 Tingting Wu and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2693–2704, 15 Development of blood culture time-to-positivity as a pharmacodynamic indicator for monitoring antibiotic therapy against MDR Gram-negative bacteria 开发血培养阳性时间作为监测针对多重耐药革兰氏阴性菌抗生素治疗的药效动力学指标 Irene Zaghi and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2705–2713, 16 In vivo activity of ceftibuten-ledaborbactam oral combination against serine-β-lactamase-producing Enterobacterales: an assessment in the pyelonephritis and cystitis murine model 头孢布坦-莱达博巴坦口服联合用药对产丝氨酸-β-内酰胺酶肠杆菌科细菌的体内活性评估：在肾盂肾炎和膀胱炎小鼠模型中的评估 Christina Koenig and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2714–2718, 17 Faecal pharmacokinetics, microbiome, and bile acid changes in healthy subjects given intravenous followed by oral omadacycline; a Phase 1 clinical trial 健康受试者静脉注射后口服奥马环素的粪便药代动力学、微生物组和胆汁酸变化：一项1期临床试验 Jinhee Jo and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2719–2726, 18 Interlaboratory comparison of a dried blood spot assay for antiretroviral adherence: implications for clinical application 抗逆转录病毒治疗依从性干血斑检测法的实验室间比对：对临床应用的启示 Nathan Engel and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2727–2731, 19 A multicentre real-life prospective cohort study on effectiveness, durability and safety of long-acting injectable cabotegravir and rilpivirine in northern Italy: the LONGITUDE study 意大利北部长效注射用卡博特韦和利匹韦林有效性、持久性和安全性的现实中多中心前瞻性队列研究：LONGITUDE研究 Maria Mazzitelli and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2732–2741, 20 Assessment of the risk of developing cefepime-induced abnormal liver enzyme levels using the albumin–bilirubin score and fibrosis-4 index: a single-centre retrospective case–control study 使用白蛋白-胆红素评分和纤维化-4指数评估头孢吡肟诱导的肝酶水平异常发生风险：一项单中心回顾性病例对照研究 Hiroki Katsu and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2742–2751, 21 Clinical course of patients with bloodstream infections enrolled in the BALANCE clinical trial BALANCE临床试验中血流感染患者的临床病程 Sean W X Ong and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2752–2758, 22 Comparative outcomes of polymyxins in neurocritical care patients with carbapenem-resistant Gram-negative bacterial pneumonia: a retrospective cohort study 神经重症患者中多黏菌素治疗碳青霉烯类耐药革兰氏阴性菌肺炎的结果比较：一项回顾性队列研究 Qian Zeng and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2759–2772, 23 Distinct population structure and genomic context of NarAB between broiler and human clinical Enterococcus isolates 肉鸡和人类临床分离的粪肠球菌中NarAB的不同群体结构和基因组背景 Jayanth Balakuntla and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2773–2781, 24 Population pharmacokinetics of bictegravir in real-world people with HIV 现实中HIV感染者比克替拉韦的群体药代动力学 Pierre Ekobena and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2782–2789, 25 Rifampicin concentrations throughout the entire treatment duration of active tuberculosis; impact of sex and body mass index 活动性肺结核整个治疗期间利福平浓度：性别和体重指数的影响 Teres Samuelsson and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2790–2798, 26 Performance of disc diffusion and gradient strip test on different Mueller–Hinton agar media plates and ComASP® and Bruker UMIC® Cefiderocol Microdilution Panels for cefiderocol susceptibility testing in carbapenem-resistant Pseudomonas aeruginosa 在碳青霉烯类耐药铜绿假单胞菌中对头孢地尔敏感性测试使用不同穆勒-欣顿琼脂培养基平板和ComASP®及Bruker UMIC®头孢地尔微量稀释板的纸片扩散法和梯度条带测试的性能 Stefano Mancini and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2799–2806, 27 Placental transfer of medications to treat COVID-19, molnupiravir, favipiravir and nirmatrelvir/ritonavir, in the ex vivo human cotyledon model 在离体人类绒毛叶模型中治疗COVID-19的药物莫努匹拉韦、法维拉韦和奈玛特韦/利托那韦的胎盘转移 Solene Labaye and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2807–2813, 28 Synergistic cefiderocol-containing antibiotic combinations active against highly drug-resistant Acinetobacter baumannii patient isolates with diverse resistance mechanisms 针对具有多种耐药机制的高度耐药鲍曼不动杆菌患者分离株的含头孢地尔抗生素联合用药的协同作用 Justin Halim and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2814–2824, 29 Uptake of drug-reduced antiretroviral strategies and impact on costs over 2015–22: experience from an HIV clinic in Paris, France 2015-2022年药物减量抗逆转录病毒策略的采用情况及对成本的影响：来自法国巴黎一家HIV诊所的经验 L Sagaon-Teyssier and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2825–2833, 30 Molecular characterization of fluoroquinolone resistance in invasive clinical isolates of Streptococcus pneumoniae susceptible to delafloxacin 对达拉氟沙星敏感的侵袭性临床肺炎链球菌分离株中氟喹诺酮耐药性的分子特征 Emilia Cercenado and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2834–2843, 31 Genomic structure of class 1 and 2 integrons in non-typhoidal Salmonella isolated from food animals and related meat products in the USA 美国食品动物及其相关肉类产品中分离的非伤寒沙门氏菌1类和2类整合子的基因组结构 Chih-Hao Hsu and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2844–2853, 32 Characterization of blaOXA-542-mediated carbapenem resistance in Acinetobacter baumannii 鲍曼不动杆菌中blaOXA-542介导的碳青霉烯类耐药性的特征 Jingchen Hao and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2854–2861, 33 Phenotypic and genotypic profiles of clinical isolates of various Nocardia species to carbapenems and fluoroquinolones 各种诺卡氏菌属临床分离株对碳青霉烯类和氟喹诺酮类的表型和基因型特征 Jing Yang and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2862–2872, RESEARCH LETTERS（研究快报） 34 Oritavancin in a patient with recurrent endocarditis by Enterococcus faecalis: a new therapeutic option? 奥利他万星治疗粪肠球菌复发性心内膜炎患者：一种新的治疗选择？ Giulia Turicchi and Marco Bongiovanni Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2873–2874, 35 The catA1 chloramphenicol resistance gene originated in Atlantibacter hermannii catA1氯霉素耐药基因起源于大西洋菌属赫尔曼尼菌 Robert A Moran and Ruth M Hall Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2874–2876, 36 Horizontal transmission of a multidrug-resistant IncM1 plasmid harbouring blaOXA-48 and blaCTX-M-14b among patient microbiotas 携带blaOXA-48和blaCTX-M-14b的多重耐药IncM1质粒在患者微生物群中的水平传播 Roberto Sierra and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2876–2879, 37 Antimicrobial activity of temocillin on ceftriaxone-resistant and ceftriaxone-susceptible isolates of Neisseria gonorrhoeae 替莫西林对头孢曲松耐药和头孢曲松敏感淋病奈瑟菌分离株的抗菌活性 Julie Brousseau and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2879–2881, LETTERS TO THE EDITOR（致编辑的信） 38 Comment on: Bactericidal activity of antibiotic combinations against clinical isolates of Enterococcus gallinarum and Enterococcus casseliflavus 述评：抗生素联合用药对临床分离的鸡肠球菌和粪肠球菌的杀菌活性 Karl Oldberg and Magnus Rasmussen Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2882–2883, 39 Comment on: Outcomes of ceftriaxone 2 g versus 1 g daily in hospitalized patients with pneumonia: a nationwide retrospective cohort study 述评：住院肺炎患者每日2克与1克头孢曲松的疗效：一项全国性回顾性队列研究 Giancarlo Ceccarelli and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2884–2885, 40 Outcomes of ceftriaxone 2 g versus 1 g daily in hospitalized patients with pneumonia: a nationwide retrospective cohort study—right to reply—authors’ response 住院肺炎患者每日2克与1克头孢曲松的疗效：一项全国性回顾性队列研究——作者回应权——作者回复 Jumpei Taniguchi and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2885–2886, Journal of Antimicrobial Chemotherapy Volume 80, Issue Supplement_4抗菌化疗杂志 80卷增刊4期 https://academic.oup.com/jac/issue/80/Supplement_4 SUPPLEMENT（补充） Two Decades of BSAC Resistance Surveillance 英国抗菌化疗学会二十年耐药性监测 FOREWORD（前言） 1 Two Decades of BSAC Resistance Surveillance 英国抗菌化疗学会二十年耐药性监测 James C Hurley and Alan P Johnson Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_4, October 2025, Page iv1, SUPPLEMENT PAPERS（补充论文） 2 Two decades of resistance surveillance by the British Society for Antimicrobial Chemotherapy: design, development, delivery, deficiencies and future directions 英国抗菌化疗学会二十年耐药性监测：设计、发展、实施、不足与未来方向 Alasdair P MacGowan and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_4, October 2025, Pages iv2–iv6, 3 The British Society for Antimicrobial Chemotherapy Resistance Surveillance Project: methods and limitations 英国抗菌化疗学会耐药性监测项目：方法与局限性 Michael Allen and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_4, October 2025, Pages iv7–iv21, 4 Antimicrobial resistance among Gram-positive agents of bacteraemia in the UK and Ireland: trends from 2001 to 2019 英国和爱尔兰地区革兰氏阳性菌血流感染病原体的抗菌药物耐药性趋势（2001 - 2019年） Rosy Reynolds and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_4, October 2025, Pages iv22–iv35, 5 Antimicrobial resistance among Gram-negative agents of bacteraemia in the UK and Ireland: trends from 2001 to 2019 英国和爱尔兰地区革兰氏阴性菌血流感染病原体的抗菌药物耐药性趋势（2001 - 2019年） Rosy Reynolds and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_4, October 2025, Pages iv36–iv48, 6 Antimicrobial resistance among agents of hospital-acquired lower respiratory tract infection in the UK and Ireland: trends from 2008/2009 to 2018/2019 英国和爱尔兰地区医院获得性下呼吸道感染病原体的抗菌药物耐药性趋势（2008/2009 - 2018/2019年） Rosy Reynolds and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_4, October 2025, Pages iv49–iv59, 7 Antimicrobial resistance among agents of community-associated lower respiratory tract infection in the UK and Ireland: trends from 1999/2000 to 2018/2019 英国和爱尔兰地区社区获得性下呼吸道感染病原体的抗菌药物耐药性趋势（1999/2000 - 2018/2019年） Rosy Reynolds and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_4, October 2025, Pages iv60–iv71, 8 Trends of serotypes and resistance among Streptococcus pneumoniae in the UK and Ireland (1999–2019) 英国和爱尔兰地区肺炎链球菌血清型及耐药性趋势（1999 - 2019年） Carolyne Horner and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_4, October 2025, Pages iv72–iv86, 9 Applications and benefits of the British Society for Antimicrobial Chemotherapy Resistance Surveillance Project—legacy and future 英国抗菌化疗学会耐药性监测项目的应用与益处——成果与未来 Benjamin J Parcell and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_4, October 2025, Pages iv87–iv95, Journal of Antimicrobial Chemotherapy Volume 80, Issue 11抗菌化疗杂志 80卷 11期 https://academic.oup.com/jac/issue VIEWPOINTS（观点） 1 Modification of antimicrobial susceptibility testing methods 抗菌药物敏感性检测方法的修改 Ian Morrissey and Jean B Patel Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 2887–2888, 2 Viewpoint: global antimicrobial stewardship accreditation is needed: the experience in Kentucky, USA 观点：需要建立全球抗菌药物管理认证体系：美国肯塔基州的经验 Ashley M Wilde and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 2889–2891, REVIEWS（综述） 3 Phages connect the biological dots of antimicrobial resistance: from genesis and spread to alternative treatment modules 噬菌体揭示抗菌药物耐药性的生物学脉络：从起源与传播到替代治疗模式 Cleo Anastassopoulou and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 2892–2901, 4 Molecular drivers of fusion plasmid: mechanistic insights and evolutionary implications 融合质粒的分子驱动因素：机制见解与进化意义 Ziyi Liu and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 2902–2911, ORIGINAL RESEARCH（研究论著） 5 Emergence of livestock-associated MRSA clonal complex 398 in Thailand’s swine industry 泰国养猪业中出现与牲畜相关的MRSA克隆复合体398 Pawarut Narongpun and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 2912–2917, 6 Peripheral neuropathy during long-term suppressive therapy with tedizolid: a case series 长期使用替达拉韦抑制治疗期间出现周围神经病变：系列病例报告 Tomaso Beringheli and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 2918–2922, 7 Low bacterial metabolism as a central mechanism of antimicrobial resistance and potential therapeutic target of staphylococcal biofilms in ventricular assist device driveline infections 细菌低代谢作为抗菌药物耐药性的核心机制及心室辅助装置驱动线感染中葡萄球菌生物膜的潜在治疗靶点 Yao Sun and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 2923–2933, 8 The pivotal role of acnA in linking carbon metabolism to virulence and antimicrobial resistance in methicillin-resistant Staphylococcus aureus acnA在连接碳代谢与耐甲氧西林金黄色葡萄球菌的毒力和抗菌药物耐药性中的关键作用 Jiahui Li and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 2934–2944, 9 Pharmacokinetics of rifampicin and isoniazid in patients with HIV–tuberculosis coinfection receiving efavirenz-based antiretroviral treatment: an ANRS12292–RIFAVIRENZ sub-study 接受以依非韦伦为基础的抗逆转录病毒治疗的HIV-结核病共感染患者中利福平和异烟肼的药代动力学：ANRS12292-RIFAVIRENZ子研究 Thibaut Gelé and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 2945–2953, 10 Novel mutations associated with clofazimine resistance in Mycobacterium intracellulare 胞内分枝杆菌中与氯法齐明耐药相关的新型突变 Xiuzhi Jiang and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 2954–2957, 11 Physiologically informed in vitro framework reveals context-dependent combinatory activity of niclosamide–colistin against Gram-negative bacteria 基于生理信息的体外框架揭示了针对革兰氏阴性菌的硝基咪唑-多粘菌素组合的情境依赖性活性 Mariana Romero-Gonzalez and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 2958–2969, 12 In vitro evolution provides insights into mechanisms of Mycoplasma genitalium resistance to moxifloxacin 体外进化揭示生殖支原体对莫西沙星的耐药机制 Teck-Phui Chua and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 2970–2977, 13 The toxin–antitoxin system SavRS contributes to vancomycin resistance in vancomycin-intermediate Staphylococcus aureus by mediating cell wall thickening 毒素-抗毒素系统SavRS通过介导细胞壁增厚促进万古霉素中间型金黄色葡萄球菌对万古霉素的耐药性 Weifeng Xu and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 2978–2988, 14 Molecular insights into carbapenemase-producing Enterobacterales from Senegal 塞内加尔产碳青霉烯酶肠杆菌目细菌的分子特征 Ousmane Sow and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 2989–3000, 15 Population pharmacokinetic model of linezolid and its metabolite PNU-142300 in elderly patients 老年患者中利奈唑胺及其代谢产物PNU-142300的群体药代动力学模型 Xianglong Chen and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3001–3010, 16 In vitro activity of contezolid and other comparators against clinical Staphylococcus and Enterococcus: a multicenter study in China 在中国开展的一项多中心研究中，康替唑胺及其他对照药物对临床分离的金黄色葡萄球菌和肠球菌的体外活性 Rongqi Lu and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3011–3020, 17 Co-existence of the oxazolidinone resistance genes cfr and optrA on a novel multiresistance plasmid from a methicillin-resistant Macrococcoides bohemicum strain 从一株耐甲氧西林的马科考代菌属波希米亚菌株中发现的携带恶唑烷酮耐药基因cfr和optrA的新型多重耐药质粒 Yao Zhu and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3021–3025, 18 Multidrug resistance and recurrence in urinary bacteraemia among cancer patients 癌症患者中尿路菌血症的多药耐药性和复发情况 Ignacio Grafia and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3026–3033, 19 Rapid replacement of blaKPC variant in ST11 carbapenem-resistant and hypervirulent Klebsiella pneumoniae contributed to ceftazidime/avibactam resistance during severe in vivo infection 在严重的体内感染期间，ST11型碳青霉烯耐药且高毒力的肺炎克雷伯菌中blaKPC变体的快速替代导致头孢他啶/阿维巴坦耐药 Ping Yang and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3034–3042, 20 Potential human health risk of carbapenem-non-susceptible Pseudomonas aeruginosa from companion animals 伴侣动物中碳青霉烯类不敏感铜绿假单胞菌对人类健康的潜在风险 Jirachaya Toyting-Hiraishi and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3043–3056, 21 Assessment of an LC coupled with tandem MS (LC-MS/MS) tool in the detection of antimicrobial resistance mechanisms in Enterobacterales 液相色谱-串联质谱（LC-MS/MS）工具在检测肠杆菌目细菌抗菌药物耐药机制中的应用评估 Anna Witkowska and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3057–3064, 22 Multidrug efflux pumps and innate azole resistance of Mucor lusitanicus 毛霉属葡萄牙菌的多药外排泵及其固有唑类耐药性 Stephanie Toepfer and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3065–3078, 23 Ivermectin dosing for children under 2 years 2岁以下儿童的伊维菌素剂量 Wenyu Yang and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3079–3081, 24 Effectiveness of first-line lamivudine/dolutegravir antiretroviral therapy in persons with HIV: real-life data from the ICONA Foundation cohort 一线拉米夫定/多替拉韦抗逆转录病毒疗法在HIV感染者中的有效性：来自ICONA基金会队列的现实数据 Alessandra Vergori and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3082–3091, 25 Eligibility and factors associated with long-acting injectable cabotegravir-rilpivirine initiation in an urban academic HIV clinic 城市学术型HIV诊所中长效注射用卡博特韦-利匹韦林启动的资格及关联因素 Geoffroy Liegeon and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3092–3100, 26 Evaluation of HIV-1 DNA resistance evolution in highly treatment-experienced and multi-resistant individuals under suppressive antiretroviral therapy: a longitudinal study from the PRESTIGIO Registry 在接受抑制性抗逆转录病毒治疗的高度治疗经验丰富和多药耐药个体中，HIV-1 DNA耐药演变的评估：来自PRESTIGIO登记处的纵向研究 D Armenia and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3101–3106, 27 Sequential antibiotic exposure restores antibiotic susceptibility 序贯抗生素暴露恢复抗生素敏感性 Farhan R Chowdhury and Brandon L Findlay Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3107–3117, 28 Dermatological adverse effects of doxycycline as post-exposure prophylaxis for sexually transmitted infections among men who have sex with men: real-world findings from a multicentre study 在男男性行为者中，使用多西环素作为性传播感染暴露后预防的皮肤科不良反应：一项多中心研究的现实发现 Ling-Ya Chen and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3118–3122, 29 Phenotype–genotype discordance in antimicrobial resistance profiles of Gram-negative uropathogens recovered from catheter-associated urinary tract infections in Egypt 埃及导管相关尿路感染中分离的革兰氏阴性尿路病原菌抗菌药物耐药性表型-基因型不一致性 Mohamed Eladawy and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3123–3132, 30 How should APOBEC3-induced resistance mutations be considered in the management of antiretroviral therapy? 在抗逆转录病毒治疗管理中，应如何考虑APOBEC3诱导的耐药突变？ Marie Gilbert and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3133–3138, 31 In vitro evaluation of olorofim and antifungal combinations against Aspergillus and Candida species 奥洛芬和抗真菌药物组合对曲霉菌和念珠菌属的体外评价 Corinne Pinder and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3139–3149, 32 Antagonistic interaction between posaconazole and olorofim in a murine model of invasive pulmonary aspergillosis 在侵袭性肺曲霉病小鼠模型中，泊沙康唑与奥洛芬之间的拮抗作用 Christopher A Darlow and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3150–3159, 33 High level of archived and circulating HIV-1 drug resistance mutations in adolescents with a detectable viremia in Cameroon 喀麦隆可检测到病毒载量的青少年中HIV-1药物耐药突变的存档和循环水平较高 Armando B D Djiyou and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3160–3164, RESEARCH LETTERS（研究快讯） 34 SCY-247, a novel second-generation triterpenoid antifungal, demonstrates high in vitro activity against genetically diverse Candida auris isolates, including FKS1 mutants 新型第二代三萜类抗真菌药物SCY-247对包括FKS1突变体在内的多种基因型耳道假丝酵母菌显示出高体外活性 Bram Spruijtenburg and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3165–3166, 35 Drug–drug interactions between tirzepatide and antiretrovirals: time to reassess and reassure? 替西帕肽与抗逆转录病毒药物之间的药物-药物相互作用：是时候重新评估和安心了吗？ Andrea Poloni and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3167–3168, 36 Does the use of topical azoles have an impact on antifungal resistance? 局部使用唑类药物对抗真菌耐药性有影响吗？ Jean-Yves Maillard Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3168–3186, 37 Leakage of cabotegravir and rilpivirine in HIV patients receiving long-acting injectable antiretroviral therapy 接受长效注射用抗逆转录病毒治疗的HIV患者中卡博特韦和利匹韦林的泄漏情况 Samir Benkouiten and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3187–3188, CORRECTION（更正） 38 Correction to: Clinical and microbiological analysis of bloodstream infections by four cefiderocol-resistant and not previously exposed NDM-producing Klebsiella pneumoniae 更正：对四种产NDM且之前未接触过头孢地洛的耐药肺炎克雷伯菌引起的血流感染的临床和微生物学分析 Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Page 3189, Journal of Antimicrobial Chemotherapy Volume 80, Issue 12抗菌化疗杂志 80卷 12期 https://academic.oup.com/jac/issue VIEWPOINT（观点） 1 Rifampicin as monotherapy for infections caused by Staphylococcus aureus: considerations for not applying ‘breakpoints in brackets’ 利福平单药治疗金黄色葡萄球菌感染：关于不应用“括号内折点”的考量 Sara E Boyd and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3191–3193, REVIEWS（综述） 2 The Achilles’ heel of the Trojan Horse? A systematic evaluation of cefiderocol susceptibility testing 特洛伊木马的致命弱点？头孢地尔药敏试验的系统评价 Deny Tsakri and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3194–3207, 3 Antifungal treatment strategies and their impact on resistance development in clinical settings 抗真菌治疗策略及其对临床环境中耐药性发展的影响 Norman Van Rhijn and P Lewis White Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3208–3226, ORIGINAL RESEARCH（论著） 4 Decrease in colistin resistance among young bovine and pig productions in France: relationship with colistin usage and stewardship measures 法国年轻牛和猪生产中多粘菌素耐药性的下降：与多粘菌素使用及管理措施的关系 Claire Chauvin and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3227–3235, 5 Time to anti-cancer treatment resumption after SARS-CoV-2 infection in patients with active haematological diseases undergoing combined antiviral treatments 接受联合抗病毒治疗的活动性血液系统疾病患者感染SARS-CoV-2后恢复抗癌治疗的时间 E Matteini and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3236–3241, 6 From TRIO to one: simplification to bictegravir/emtricitabine/tenofovir alafenamide in highly treatment-experienced people living with MDR HIV 从三联疗法到单一疗法：在多重耐药HIV感染且治疗经验丰富的人群中简化使用比克替拉韦/恩曲他滨/丙酚替诺福韦 José L Casado and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3242–3247, 7 Effects of commonly used antibiotics on children’s developing gut microbiomes and resistomes in peri-urban Lima, Peru 秘鲁利马市郊常用抗生素对儿童发育中的肠道微生物组和耐药组的影响 Neha Sehgal and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3248–3256, 8 Frailty Index Laboratory (FI-Lab) as predictor of poor outcomes for intra-hospital multidrug-resistant Klebsiella pneumoniae bloodstream infections: a single-centre retrospective cohort study 衰弱指数实验室（FI-Lab）作为预测院内多重耐药肺炎克雷伯菌血流感染不良预后的指标：一项单中心回顾性队列研究 Carmen Pellegrino and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3257–3264, 9 Mechanisms of resistance to ceftazidime/avibactam in mutants derived in vitro from Klebsiella pneumoniae producing OXA-48-like enzymes 体外衍生的产OXA-48样酶肺炎克雷伯菌突变体对头孢他啶/阿维巴坦的耐药机制 T Blanco-Martín and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3265–3272, 10 Comparative evaluation of disc diffusion and broth microdilution methods for aztreonam/avibactam susceptibility testing in Enterobacterales 肠杆菌目中氨曲南/阿维巴坦药敏试验的纸片扩散法和肉汤微量稀释法的比较评价 Ioannis Baltas and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3273–3277, 11 Efficacy of topical hydrophilic gel of paromomycin combined with systemic or locally administered leishmanicidal drugs for treatment of experimental leishmaniasis caused by Leishmania (Viannia) braziliensis 硫酸巴龙霉素亲水性凝胶局部用药联合全身或局部使用杀利什曼原虫药物治疗巴西利什曼原虫（Viannia亚属）引起的实验性利什曼病的疗效 Líndicy Leidicy Alves and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3278–3287, 12 Population pharmacokinetics and dosing optimization of cefoselis in paediatric patients with haematological malignancies 血液系统恶性肿瘤患儿中头孢噻利的群体药代动力学及剂量优化 Jing-Rui Liu and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3288–3296, 13 Therapeutic challenges in treating ESBL- and/or AmpC-producing non-carbapenemase-producing Enterobacterales: an in vitro evaluation of novel β-lactam/β-lactamase inhibitor combinations and cefiderocol 治疗产超广谱β-内酰胺酶（ESBL）和/或AmpC酶且不产碳青霉烯酶的肠杆菌目细菌的挑战：新型β-内酰胺/β-内酰胺酶抑制剂组合和头孢地尔的体外评价 Inès Rezzoug and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3297–3305, 14 Post-exposure prophylaxis with doxycycline (DoxyPEP) to prevent STIs in a real-world setting: the PRIDOX study 使用多西环素进行暴露后预防（DoxyPEP）以在现实环境中预防性传播感染：PRIDOX研究 R Palacios and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3306–3310, 15 Risk–benefit balance of blood cultures among patients with stage IV cancer in unplanned admission: a nationwide propensity score–weighted study in Japan 日本全国范围内倾向评分加权研究：IV期癌症患者非计划入院时血培养的风险-获益平衡 Yuki Hashimoto and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3311–3319, 16 A drug-repurposing screen of FDA- and EMA-approved drugs identifies two NF-κB inhibitors active against eumycetoma 对美国食品药品监督管理局（FDA）和欧洲药品管理局（EMA）批准的药物进行药物再利用筛选，发现两种对真性着色真菌病有活性的NF-κB抑制剂 Jingyi Ma and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3320–3328, 17 Temocillin versus other intravenous beta-lactams for urinary tract infections caused by third-generation cephalosporin-resistant Enterobacterales: a multicentre retrospective matched cohort study 替莫西林与其他静脉注射β-内酰胺类药物治疗第三代头孢菌素耐药肠杆菌目引起的尿路感染：一项多中心回顾性匹配队列研究 Jeanne Iachkine and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3329–3334, 18 Treatment preferences by infectious diseases clinicians for carbapenem-resistant Enterobacterales infections 感染科医生对碳青霉烯耐药肠杆菌目感染的治疗偏好 Samuel E Cincotta and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3335–3339, 19 The aphA1 kanamycin and neomycin resistance gene originated in Klebsiella michiganensis aphA1卡那霉素和新霉素耐药基因起源于密歇根克雷伯菌 Robert A Moran and Ruth M Hall Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3340–3344, 20 Global susceptibility profiles and potential resistance mechanisms of ceftazidime–avibactam-resistant, non-carbapenemase-producing carbapenem-resistant Enterobacterales: 2020–23 data from the Antimicrobial Testing Leadership and Surveillance 头孢他啶-阿维巴坦耐药且不产碳青霉烯酶的碳青霉烯耐药肠杆菌目的全球易感性特征和潜在耐药机制：2020-2023年来自抗菌药物测试领导与监测的数据 Chih-Cheng Lai and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3345–3351, 21 Comparative in vitro activity of ceftazidime-avibactam plus aztreonam and the fixed combination aztreonam/avibactam against multidrug-resistant Pseudomonas aeruginosa 头孢他啶-阿维巴坦联合氨曲南与固定组合氨曲南/阿维巴坦对多重耐药铜绿假单胞菌的体外活性比较 Sophie E Müller and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3352–3356, 22 Dual β-lactam synergy in Enterococcus faecalis and its relationship with penicillin-ceftriaxone infective endocarditis treatment outcomes 粪肠球菌中双重β-内酰胺协同作用及其与青霉素-头孢曲松感染性心内膜炎治疗结果的关系 April Gregson and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3357–3366, 23 The long walk to a short half-life: the discovery of augmented renal clearance and its impact on antibiotic dosing 走向短半衰期的漫长之路：发现肾增强清除及其对抗菌药物剂量调整的影响 Jeffrey Lipman and Russell E Lewis Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3367–3374, 24 Aztreonam-amoxicillin/clavulanate combination therapy against blaNDM-producing Enterobacterales infections 氨曲南-阿莫西林/克拉维酸联合治疗产blaNDM肠杆菌目感染 Efrat Orenbuch-Harroch and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3375–3380, 25 Evaluation of sodium zirconium cyclosilicate usage for hyperkalaemia secondary to sulfamethoxazole/trimethoprim therapy 评估锆酸钠环硅酸盐用于磺胺甲恶唑/甲氧苄啶治疗继发的高钾血症 Dixie Pyles and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3381–3385, 26 Thrice-weekly post-haemodialysis ceftazidime can achieve adequate pre-dialysis concentrations and clinical cure in patients with melioidosis 每周三次血液透析后使用头孢他啶可在类鼻疽患者中达到足够的透析前浓度并实现临床治愈 Simon Smith and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3386–3390, 27 In vitro and clinical data demonstrate negligible risk of drug–drug interactions with opelconazole, a novel inhaled antifungal agent 体外和临床数据表明，新型吸入抗真菌药物奥培康唑的药物-药物相互作用风险可忽略不计 Lindsey M R Cass and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3391–3400, 28 Antifungal prophylaxis in patients with FMS-like tyrosine kinase 3-internal tandem duplication (FLT3-ITD)–positive acute myeloid leukaemia receiving sorafenib during initial induction and consolidation treatment in ALLG AMLM16 trial 在ALLG AMLM16试验中，FLT3-ITD阳性急性髓系白血病患者在初始诱导和巩固治疗期间接受索拉非尼治疗时的抗真菌预防 Chin Fen Neoh and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3401–3406, 29 The synergistic activity of tigecycline-based combinations against multidrug-resistant Acinetobacter baumannii-caused bloodstream infections 基于替加环素的联合用药对多重耐药鲍曼不动杆菌引起的血流感染的协同活性 Huan Zhang and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3407–3418, 30 Piperacillin dosing in pediatric patients and augmented renal clearance: are current guidelines sufficient to achieve therapeutic concentration coverage? 儿科患者中哌拉西林的剂量调整与肾增强清除：现行指南是否足以达到治疗浓度覆盖？ Anne Ravix and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3419–3430, 31 Efficacy of human-simulated aztreonam-avibactam against Stenotrophomonas maltophilia in the neutropenic murine thigh infection model 在中性粒细胞减少的小鼠大腿感染模型中评估人模拟氨曲南-阿维巴坦对嗜麦芽窄食单胞菌的疗效 Yakun Fu and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3431–3437, 32 A prospective assessment of the efficacy and durability of long-acting cabotegravir and rilpivirine in individuals with HIV in Spain (RELATIVITY study) 西班牙HIV感染者长期使用卡博特韦和利匹韦林的有效性和持久性的前瞻性评估（RELATIVITY研究） Luis Buzón-Martín and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3438–3451, 33 Antagonistic in vitro interaction between olorofim and voriconazole against Aspergillus fumigatus 奥洛罗芬和伏立康唑对烟曲霉的体外拮抗作用 Illan Laloum and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3452–3461, RESEARCH LETTERS（研究快讯） 34 Concomitant IV vancomycin causing delayed high-dose methotrexate clearance and acute kidney injury 静脉注射万古霉素联用导致大剂量甲氨蝶呤清除延迟和急性肾损伤 Thao Dao and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3462–3464, 35 Overestimation of piperacillin/tazobactam resistance in Escherichia coli by disc diffusion and gradient strip methods 纸片扩散法和梯度条法高估大肠埃希菌对哌拉西林/他唑巴坦的耐药性 Stefano Mancini and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3464–3467, 36 Mind the gap: missed re-initiation and monitoring in statin–antimicrobial co-prescriptions 注意差距：他汀类药物与抗菌药物联合处方中的漏重新起始和监测 Melwin Kyle Solis and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3467–3468, 37 Pharmacokinetics of aztreonam/avibactam in a critically ill patient with a class B metallo-β-lactamase producing Enterobacteriaceae and receiving continuous renal replacement therapy 一名接受连续肾脏替代治疗且感染产B类金属β-内酰胺酶肠杆菌科细菌的重症患者中氨曲南/阿维巴坦的药代动力学 Daniel Fresán and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3469–3471, CORRECTION（更正） 38 Correction to: Systematic reviews and the Journal of Antimicrobial Chemotherapy; past, present and future. A systematic reappraisal 更正：系统评价与《抗菌药物化疗杂志》：过去、现在和未来。一项系统再评价 Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3472–3473,

100 项与德拉马尼相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D09785	德拉马尼	J04AK06	DB11637

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
结核	中国	Otsuka Pharmaceutical Co., Ltd.	2018-02-17
肺结核	日本	Otsuka Holdings Co., Ltd.	2014-07-04
耐多药结核病	欧盟	Otsuka Novel Products GmbH	2014-04-27
耐多药结核病	冰岛	Otsuka Novel Products GmbH	2014-04-27
耐多药结核病	列支敦士登	Otsuka Novel Products GmbH	2014-04-27
耐多药结核病	挪威	Otsuka Novel Products GmbH	2014-04-27

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
多重耐药性肺结核	临床3期	美国	Otsuka Pharmaceutical Development & Commercialization, Inc.	2011-09-02
多重耐药性肺结核	临床3期	爱沙尼亚	Otsuka Pharmaceutical Development & Commercialization, Inc.	2011-09-02
多重耐药性肺结核	临床3期	拉脱维亚	Otsuka Pharmaceutical Development & Commercialization, Inc.	2011-09-02
多重耐药性肺结核	临床3期	立陶宛	Otsuka Pharmaceutical Development & Commercialization, Inc.	2011-09-02
多重耐药性肺结核	临床3期	秘鲁	Otsuka Pharmaceutical Development & Commercialization, Inc.	2011-09-02
多重耐药性肺结核	临床3期	菲律宾	Otsuka Pharmaceutical Development & Commercialization, Inc.	2011-09-02
多重耐药性肺结核	临床3期	南非	Otsuka Pharmaceutical Development & Commercialization, Inc.	2011-09-02
HIV感染	临床2期	印度	Otsuka Pharmaceutical Development & Commercialization, Inc.	2018-01-30
HIV感染	临床2期	南非	Otsuka Pharmaceutical Development & Commercialization, Inc.	2018-01-30
HIV感染	临床2期	坦桑尼亚	Otsuka Pharmaceutical Development & Commercialization, Inc.	2018-01-30

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03959566 (PanACEA-SUDOCU-01, Pubmed \| Lancet Infect Dis)	临床2期	肺结核一线	75	Sutezolid 600 mg once daily	積壓鏇夢窪淵膚夢鑰廠(鏇淵鏇醖選膚糧襯糧膚) = grade 4 adverse event in the Sutezolid 800 mg twice daily group 醖糧壓獵憲鹹顧繭鏇製 (鬱鹹糧築膚醖範簾醖憲 ) 更多	积极	2025-11-01
				Sutezolid 600 mg twice daily
NCT04421495 (Pubmed \| Front Med (Lausanne))	临床4期	利福平耐药结核病	33	Delamanid 100 mg + optimized background regimen (OBR)	製顧壓簾鹽簾膚襯糧襯(鑰觸繭願鑰築願獵鹹齋) = 窪夢壓齋餘壓窪選鑰膚醖鏇顧壓製獵願膚選積 (窪憲觸襯壓製顧衊衊糧 ) 更多	积极	2025-09-29
NTBERC (ATS2025)	N/A	利福平耐药结核病	-	Bedaquiline	餘願餘艱鏇範衊醖選餘(遞糧願積襯築顧鬱廠築) = 膚襯衊選願製簾蓋襯鏇鏇壓鹹襯顧顧壓憲壓顧 (壓夢願簾襯醖衊觸醖齋 )	积极	2025-05-16
				Delamanid	餘願餘艱鏇範衊醖選餘(遞糧願積襯築顧鬱廠築) = 構窪廠鏇淵齋憲顧艱繭鏇壓鹹襯顧顧壓憲壓顧 (壓夢願簾襯醖衊觸醖齋 )
NCT02619994 (MDR-END, CTgov)	临床2期	耐多药结核病	214	Locally-used WHO-approved MDR-TB regimen in Korea (Control Arm)	鏇鑰膚鏇遞艱願願製夢 = 選觸繭糧鏇範餘簾廠鬱製築齋醖鏇鬱獵壓衊鏇 (願醖淵淵夢膚齋醖製糧, 鏇糧鑰獵鏇簾齋築壓構 ~ 膚壓鹹餘蓋顧鬱鹹鹹艱) 更多	-	2025-01-03
				levofloxacin+Linezolid+Delamanid+Pyrazinamide (Experimental Arm)	鏇鑰膚鏇遞艱願願製夢 = 繭廠鹽窪窪鬱糧構範網製築齋醖鏇鬱獵壓衊鏇 (願醖淵淵夢膚齋醖製糧, 獵網窪膚遞廠夢構餘壓 ~ 齋鏇壓艱遞窪憲襯遞襯) 更多
NCT03896685 (endTB-Q, Pubmed)	临床3期	耐多药结核病	324	Bedaquiline, Linezolid, Clofazimine, Delamanid	膚網鏇製襯顧觸觸壓觸(淵艱觸積衊蓋鏇遞構醖) = 齋製壓選襯壓願繭鏇範遞網築願積壓糧積壓鹹 (淵鹽獵鏇獵願製艱鏇蓋 )	积极	2023-11-30
				Contemporaneous WHO standard of care for pre-XDR TB	膚網鏇製襯顧觸觸壓觸(淵艱觸積衊蓋鏇遞構醖) = 艱艱膚簾鏇簾獵選淵壓遞網築願積壓糧積壓鹹 (淵鹽獵鏇獵願製艱鏇蓋 )
NCT01859923 \| NCT01856634 (Pubmed \| Antimicrob Agents Chemother) 人工标引	临床1/2期	耐多药结核病	37	Delamanid	糧獵觸築憲蓋範窪糧顧(觸鏇積窪積醖鹹遞範壓) = 選顧繭選艱製醖遞膚鏇構構鹹廠餘願鏇獵簾艱 (繭顧鬱艱構積醖鏇遞醖 ) 更多	积极	2022-04-11
NCT00685360 (CTgov)	临床2期	广泛耐药结核病 \| 多重耐药性肺结核	481	Placebo+Delamanid (Delamanid 100 mg BID + OBR)	簾願齋衊鏇遞糧襯簾範 = 膚糧網築鏇衊鏇網繭遞積築築願膚遞積鏇鬱廠 (鏇積廠廠簾鑰顧構繭願, 構積願鹽蓋築簾鑰憲壓 ~ 襯選鹽餘範衊網鹽選餘) 更多	-	2021-12-01
				Optimized Background Regimen (OBR)+Delamanid (Delamanid 200 mg BID + OBR)	簾願齋衊鏇遞糧襯簾範 = 夢獵願願淵鬱觸鏇選餘積築築願膚遞積鏇鬱廠 (鏇積廠廠簾鑰顧構繭願, 艱壓醖鬱簾壓鹽齋齋廠 ~ 繭醖構築鏇鹽憲鑰醖醖) 更多
NCT01131351 (CTgov)	临床2期	多重耐药性肺结核 \| 耐多药结核病	10	OBR+Delamanid (Delamanid 250 mg BID + OBR)	壓鹽積衊鑰鑰範膚簾衊 = 衊蓋鬱積艱鏇鹹觸製製選獵鹹窪製淵鏇顧築蓋 (鹽積顧鬱築觸獵積廠糧, 鑰鹽鏇夢窪衊廠網網艱 ~ 觸窪遞構獵壓網淵鑰繭) 更多	-	2021-11-11
				OBR+Delamanid (Delamanid 300 mg BID + OBR)	壓鹽積衊鑰鑰範膚簾衊 = 繭遞選鏇顧鏇鏇願獵簾選獵鹹窪製淵鏇顧築蓋 (鹽積顧鬱築觸獵積廠糧, 範憲繭襯衊顧夢餘築選 ~ 製選蓋範淵餘製淵鑰積) 更多
NCT02573350 (CTgov)	临床2期	多重耐药性肺结核 \| 耐多药结核病	213	OBR+Delamanid (Delamanid 100 mg BID + OBR)	鬱積糧廠構餘鬱窪蓋鹽 = 鹽窪選艱顧膚鏇簾衊憲遞齋顧蓋繭窪獵夢顧壓 (製衊醖衊範獵鏇鹹範獵, 蓋願廠鹹廠願膚構願膚 ~ 廠齋衊簾艱製遞鑰糧網) 更多	-	2021-11-01
				OBR+Delamanid (Delamanid 200 mg BID + OBR)	鬱積糧廠構餘鬱窪蓋鹽 = 餘鬱衊齋築範鏇齋鹹製遞齋顧蓋繭窪獵夢顧壓 (製衊醖衊範獵鏇鹹範獵, 鏇製鏇蓋鑰糧簾鬱製衊 ~ 簾簾淵艱鹹襯簾廠顧顧) 更多
NCT02583048 (ACTG A5343, Pubmed \| Lancet Infect Dis)	临床2期	利福平耐药结核病	84	Bedaquiline	夢鑰鏇繭衊鏇餘鹹廠醖(築遞糧憲糧糧範網願鏇) = 糧蓋鏇遞顧鬱醖窪艱遞衊衊夢壓蓋餘憲鹹醖齋 (遞憲膚鹽網鏇鹹網壓壓, 71 ~ 97)	积极	2021-02-12
				Delamanid	夢鑰鏇繭衊鏇餘鹹廠醖(築遞糧憲糧糧範網願鏇) = 網糧網獵選糧鬱積醖窪衊衊夢壓蓋餘憲鹹醖齋 (遞憲膚鹽網鏇鹹網壓壓, 65 ~ 95)